Short answer
ARTIVION, INC. (AORT) filed its Q2 2026 10-Q quarterly report on Aug 7, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $126M (up 11.3% year over year) with net income of −$14M.
Q2 2026 key financials · XBRL
- Revenue
- $126M
- +11.3% YoY · +8.1% QoQ
- Net income
- −$14M
- −1104.5% YoY · −1053.4% QoQ
- Operating margin
- -6.7%
- Gross margin
- 64.0%
- EPS (diluted)
- −$0.28
- −1033.3% YoY · −1033.3% QoQ
Source: XBRL data from the ARTIVION, INC. (AORT) Q2 2026 10-Q on SEC EDGAR. USD.
ARTIVION, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $125.8M, up 11% YoY from $113.0M; constant-currency growth 9%
- Gross margin 64% vs 65% YoY; G&A and marketing 63% of revenue vs 51%
- Best performer: On-X revenue $30.5M, up 19%; worst: surgical sealants $19.3M, flat
- Product revenue $99.9M, up 14%; aortic stent grafts $46.4M, up 16%
- Near-term headwinds: seasonal third-quarter demand declines and foreign-exchange volatility
Risk Factors
- Newly triggered geopolitical supply risk: Endospan acquisition completed May 18, 2026, adding sole-source NEXUS manufacturing in Herzliya, Israel
- Regulatory risk: Italian government assessing 2019–2024 medical-device repayments, with estimated 2019–2025 exposure of approximately $2.3 million
- Tissue-preservation compliance risk: FDA draft tuberculosis guidance could significantly reduce safe implantable human-tissue supply if implemented
- Competitive risk: GLP-1 drugs may create investor and customer confusion and pressure perceived product demand
- Currency risk: Most foreign revenues denominated in Euros, exposing revenue and margins to exchange-rate fluctuations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARTIVION, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.